Kartik S, Pal R, Chaudhary M, Nath R, Kumar M
Ann Neurosci. 2025; 31(4):265-276.
PMID: 39840143
PMC: 11744622.
DOI: 10.1177/09727531231191661.
Roberts C, Raabe N, Wiegand L, Kadar Shahib A, Rastegar M
Pharmaceuticals (Basel). 2025; 17(12.
PMID: 39770443
PMC: 11677501.
DOI: 10.3390/ph17121601.
Sian-Hulsmann J, Riederer P, Michel T
Biomedicines. 2025; 12(12.
PMID: 39767747
PMC: 11673947.
DOI: 10.3390/biomedicines12122841.
Hattori N, Sato S
J Neural Transm (Vienna). 2024; 131(12):1415-1428.
PMID: 39585446
DOI: 10.1007/s00702-024-02863-2.
Riaz Z, Richardson G, Jin H, Zenitsky G, Anantharam V, Kanthasamy A
Mol Neurodegener. 2024; 19(1):87.
PMID: 39578912
PMC: 11585115.
DOI: 10.1186/s13024-024-00774-0.
Ketone ester-enriched diet ameliorates motor and dopamine release deficits in MitoPark mice.
Mahajan V, Nadel J, King M, Pawlosky R, Davis M, Veech R
Eur J Neurosci. 2024; 60(11):6875-6890.
PMID: 39528410
PMC: 11612846.
DOI: 10.1111/ejn.16601.
Heterozygous loss of Engrailed-1 and α-synucleinopathy (En1/SYN): A dual-hit preclinical mouse model of Parkinson's disease, analyzed with artificial intelligence.
Stetzik L, Mercado G, Steiner J, Lindquist A, Gilliland C, Schulz E
Neurobiol Dis. 2024; 200:106647.
PMID: 39187209
PMC: 11513166.
DOI: 10.1016/j.nbd.2024.106647.
Revolutionizing our understanding of Parkinson's disease: Dr. Heinz Reichmann's pioneering research and future research direction.
Tanaka M, Vecsei L
J Neural Transm (Vienna). 2024; 131(12):1367-1387.
PMID: 39110245
PMC: 11608389.
DOI: 10.1007/s00702-024-02812-z.
Rethinking Parkinson's disease: could dopamine reduction therapy have clinical utility?.
Sackner-Bernstein J
J Neurol. 2024; 271(8):5687-5695.
PMID: 38904783
PMC: 11319508.
DOI: 10.1007/s00415-024-12526-7.
Dysregulation of SNX1-retromer axis in pharmacogenetic models of Parkinson's disease.
Yoshida S, Hasegawa T, Nakamura T, Sato K, Sugeno N, Ishiyama S
Cell Death Discov. 2024; 10(1):290.
PMID: 38886344
PMC: 11183211.
DOI: 10.1038/s41420-024-02062-8.
Pathological mechanisms and treatment of sporadic Parkinson's disease: past, present, and future.
Mochizuki H
J Neural Transm (Vienna). 2024; 131(6):597-607.
PMID: 38864935
PMC: 11192660.
DOI: 10.1007/s00702-024-02788-w.
Role of Epigenetic Modulation in Neurodegenerative Diseases: Implications of Phytochemical Interventions.
Prasanth M, Sivamaruthi B, Cheong C, Verma K, Tencomnao T, Brimson J
Antioxidants (Basel). 2024; 13(5).
PMID: 38790711
PMC: 11118909.
DOI: 10.3390/antiox13050606.
Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice.
Wang V, Tseng K, Kuo T, Yi-Kung Huang E, Lan K, Chen Z
J Biomed Sci. 2024; 31(1):38.
PMID: 38627765
PMC: 11022395.
DOI: 10.1186/s12929-024-01025-6.
Mitochondria Dysfunction and Neuroinflammation in Neurodegeneration: Who Comes First?.
Peggion C, Cali T, Brini M
Antioxidants (Basel). 2024; 13(2).
PMID: 38397838
PMC: 10885966.
DOI: 10.3390/antiox13020240.
Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson's disease.
Naoi M, Maruyama W, Shamoto-Nagai M, Riederer P
J Neural Transm (Vienna). 2024; 131(6):639-661.
PMID: 38196001
DOI: 10.1007/s00702-023-02730-6.
Involvement of Mitochondria in Parkinson's Disease.
Choong C, Mochizuki H
Int J Mol Sci. 2023; 24(23).
PMID: 38069350
PMC: 10707101.
DOI: 10.3390/ijms242317027.
Mitochondrial dysfunction in Parkinson's disease - a key disease hallmark with therapeutic potential.
Henrich M, Oertel W, Surmeier D, Geibl F
Mol Neurodegener. 2023; 18(1):83.
PMID: 37951933
PMC: 10640762.
DOI: 10.1186/s13024-023-00676-7.
Catecholamines and Parkinson's disease: tyrosine hydroxylase (TH) over tetrahydrobiopterin (BH4) and GTP cyclohydrolase I (GCH1) to cytokines, neuromelanin, and gene therapy: a historical overview.
Nagatsu T
J Neural Transm (Vienna). 2023; 131(6):617-630.
PMID: 37638996
DOI: 10.1007/s00702-023-02673-y.
Impaired aldehyde detoxification exacerbates motor deficits in an alpha-synuclein mouse model of Parkinson's disease.
Martinez P, Martinez V, Rani S, Murrell M, Javors M, Gelfond J
Brain Behav. 2023; 13(9):e3150.
PMID: 37452461
PMC: 10498093.
DOI: 10.1002/brb3.3150.
The Impact of microRNAs on Mitochondrial Function and Immunity: Relevance to Parkinson's Disease.
Guedes B, Cardoso S, Esteves A
Biomedicines. 2023; 11(5).
PMID: 37239020
PMC: 10215921.
DOI: 10.3390/biomedicines11051349.